Evaluating the Safety of HCAR19 (Now Actalycabtagene Autoleucel- Actaly-CelT), a Novel Humanized CD19-Directed Chimeric Antigen Receptor T-Cells in Pediatric, Adolescents, and Young Adults with Relapsed/ Refractory B- Acute Lymphoblastic Leukemia (ESHA) - Report of Phase-1B

被引：2

作者：

Narula, Gaurav ^{[1
]}

Keerthivasagam, Swaminathan ^{[2
]}

Jain, Hasmukh ^{[1
]}

Dhamne, Chetan ^{[2
]}

Tembhare, Prashant ^{[3
]}

Subramanian, Papagudi Ganesan ^{[3
]}

Patkar, Nikhil ^{[3
]}

Poojary, Minal ^{[4
]}

Nisar, Albeena ^{[5
]}

Pandit, Deepali ^{[6
]}

Pandit, Khushali ^{[7
]}

Karulkar, Atharva ^{[8
]}

Jaiswal, Ankesh Kumar ^{[8
]}

Khan, Aalia ^{[8
]}

Shah, Shreshtha ^{[8
,9
]}

Firfiray, Afrin ^{[8
]}

Pendhari, Juber ^{[8
]}

Asija, Sweety ^{[8
]}

Chowdury, Ambalika ^{[8
]}

Banik, Ankit ^{[8
]}

Moulik, Nirmalya Roy ^{[2
]}

Srinivasan, Shyam ^{[10
]}

Bhosle, Shilpushp ^{[11
]}

Hiregoudar, Sumathi ^{[3
]}

Ojha, Shashank ^{[3
]}

Nayak, Lingaraj ^{[3
,12
]}

Thorat, Jayshree ^{[13
]}

Bagal, Bhausaheb ^{[3
,12
]}

Sengar, Manju ^{[1
]}

Jindal, Nishant ^{[3
,12
]}

Chichra, Akanksha ^{[12
]}

Mirgh, Sumeet ^{[3
,12
]}

Gokarn, Anant ^{[3
,12
]}

Punatar, Sachin ^{[3
,12
]}

Rajadhyaksha, Sunil ^{[14
]}

Khattry, Navin ^{[3
,12
]}

Banavali, Shripad ^{[15
]}

Highfill, Steven ^{[16
]}

Shah, Nirali N. ^{[17
]}

Purwar, Rahul ^{[18
]}

机构：

[1] Homi Bhabha Natl Inst, Dept Med Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India

[2] Homi Bhabha Natl Inst, Dept Pediat Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India

[3] Homi Bhabha Natl Inst, Dept Hematopathol, Tata Mem Ctr, Adv Ctr Treatment Res & Educ Canc ACTREC, Navi Mumbai, India

[4] Homi Bhabha Natl Inst, Dept Transfus Med, Tata Mem Ctr, Navi Mumbai, India

[5] ACTREC, CAR T & Cell Therapy Ctr, Tata Mem Ctr, Sci Off D, Mumbai, Maharashtra, India

[6] Tata Mem Hosp, CAR T & Cell Therapy Ctr, ACTREC, Kharghar, India

[7] Tata Mem Hosp, CAR T & Cell Therapy Ctr, ACTREC, Mumbai, Maharashtra, India

[8] Indian Inst Technol, Dept Biosci & Bioengn, Mumbai, Maharashtra, India

[9] ImmunoACT, Immunoadopt Cell Therapy Private Ltd, Mumbai, Maharashtra, India

[10] Homi Bhabha Natl Inst, Dept Pediat Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India

[11] Homi Bhabha Natl Inst, Dept Crit Care & Anaesthesiol, Tata Mem Ctr, Mumbai, Maharashtra, India

[12] Homi Bhabha Natl Inst, Dept Med Oncol, BMT Unit,Tata Mem Ctr, Adv Ctr Treatment Res & Educ Canc ACTREC, Navi Mumbai, India

[13] Homi Bhabha Natl Inst, Dept Med Oncol, Tata Mem Ctr, Mumbai, Maharashtra, India

[14] Homi Bhabha Natl Inst, Dept Transfus Med, Tata Mem Ctr, Mumbai, Maharashtra, India

[15] Tata Mem Hosp, Dept Med Oncol, Homi Bhabha Natl Inst, Mumbai, Maharashtra, India

[16] Natl Inst Hlth, Ctr Cellular Engn, Bethesda, MD USA

[17] Natl Inst Hlth, Pediat Oncol Branch, Bethesda, MD USA

[18] Indian Inst Technol B, Dept Biosci & Bioengn, Mumbai, Maharashtra, India

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180867

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 28 条

[21] UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
Benjamin, Reuben
Jain, Nitin
Maus, Marcela V.
Boissel, Nicolas
Graham, Charlotte
Jozwik, Agnieszka
Yallop, Deborah
Konopleva, Marina
Frigault, Matthew J.
Teshima, Takanori
Kato, Koji
Boucaud, Floriane
Balandraud, Svetlana
Gianella-Borradori, Athos
Binlich, Florence
Marchiq, Ibtissam
Dupouy, Sandra
Almena-Carrasco, Maria
Pannaux, Matthieu
Fouliard, Sylvain
Brissot, Eolia
Mohty, Mohamad
LANCET HAEMATOLOGY, 2022, 9 (11): : E833 - E843
[22] Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
Topp, M. S.
Shah, B. D.
Ghobadi, A.
Oluwole, O. O.
Logan, A. C.
Boissel, N.
Cassaday, R. D.
Forcade, E.
Bishop, M. R.
Tzachanis, D.
O'Dwyer, K. M.
Arellano, M. L.
Lin, Y.
Baer, M. R.
Schiller, G. J.
Dong, J.
Shen, T.
Milletti, F.
Masouleh, Kharabi B.
Houot, R.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 16 - 16
[23] ZUMA-4: A phase 1/2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in pediatric and adolescent subjects with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).
Wayne, Alan S.
Sender, Leonard S.
Lee, Daniel Warnell
Handgretinger, Rupert
Brown, Patrick A.
Jiang, Yizhou
Navale, Lynn
Stout, Shanna
Aycock, Jeff
Wiezorek, Jeffrey S.
Jain, Rajul K.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[24] Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Shah, Bijal D.
Ghobadi, Armin
Oluwole, Olalekan O.
Logan, Aaron
Boissel, Nicolas
Cassaday, Ryan Daniel
Forcade, Edouard
Bishop, Michael Russell
Topp, Max S.
Tzachanis, Dimitrios
O'Dwyer, Kristen M.
Arellano, Martha Lucia
Lin, Yi
Baer, Maria R.
Schiller, Gary J.
Dong, Jinghui
Shen, Tong
Milletti, Francesca
Masouleh, Behzad Kharabi
Houot, Roch
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[25] Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy Targeting CD19 and CD22, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Amrolia, Persis J.
Wynn, Robert
Hough, Rachael E.
Vora, Ajay
Bonney, Denise
Veys, Paul
Chiesa, Robert
Rao, Kanchan
Clark, Liz
Al-Hajj, Muhammad
Cordoba, Shaun P.
Onuoha, Shimobi
Kotsopoulou, Ekaterini
Khokhar, Nushmia Z.
Pule, Martin
Peddareddigari, Vijay G. R.
BLOOD, 2019, 134
[26] Simultaneous Targeting of CD19 and CD22: Phase I Study of AUTO3, a Bicistronic Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (r/r B-ALL): Amelia Study
Amrolia, Persis J.
Wynn, Robert
Hough, Rachael
Vora, Ajay
Bonney, Denise
Veys, Paul
Rao, Kanchan
Chiesa, Robert
Al-Hajj, Muhammad
Cordoba, Shaun P.
Onuoha, Shimobi
Kotsopoulou, Ekaterini
Khokhar, Nushmia Z.
Pule, Martin
Peddareddigari, Vijay G. R.
BLOOD, 2018, 132
[27] Interim Safety Analysis: a Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed By Infusion of Chimeric Antigen Receptor Modified T-Cells (19-28z CAR-T) Directed Against CD19+B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma (B-NHL)
Sauter, Craig S.
Riviere, Isabelle
Bernal, Yvette J.
Wang, Xiuyan
Purdon, Terence J.
Yoo, Sarah
Moskowitz, Craig H.
Giralt, Sergio
Matasar, Matthew J.
Curran, Kevin J.
Park, Jae H.
Sadelain, Michel
Brentjens, Renier J.
BLOOD, 2014, 124 (21)
[28] A Phase I Clinical Trial of Point-of-Care Manufactured Fresh Anti-CD19/20/22 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Lymphoid Malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, B Prolymphocytic Leukemia)
Vasu, Sumithira
Alinari, Lapo
Szuminski, Nicole
Schneider, Dina
Denlinger, Nathan
Chan, Wing Keung
Parris, Khalid
Sharma, Nidhi
Bradbury, Hillary
Daneault, Beth
O'Donnell, Lynn
Dropulic, Boro
de Lima, Marcos J. G.
BLOOD, 2022, 140 : 7474 - 7475

← 1 2 3 →